About: Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Sector: Healthcare
Industry: Biotechnology
Latest price: $15.02 (-2.28%)
AAPG NASDAQ Ascentage Pharma Group International
Ascentage Pharma Group International share price
AAPG price activity
Last Price
$15.020
Change (24hr)
-0.35 USD (-2.28%)
Volume
1.40K
Volume (4w avg)
-
Open
$15.37
Day Range
$15.02 - $15.37
Previous Close
$15.37
Last Trade
18 Sep, 4:34 pm GMT+0
Delayed
18 Sep, 4:34 pm GMT+0
AAPG price performance
Delayed
18 Sep, 4:34 pm GMT+0
AAPG Market Signals